Bioventus Appoints Katrina Church Chief Compliance Officer
DURHAM, NC – August 24, 2020 – Bioventus, a global leader in orthobiologic solutions, has appointed Katrina Church as its Chief Compliance Officer, effective August 24, 2020. Church brings more than 20 years of experience counseling public and private companies to ensure the highest compliance with industry standards, reporting and controls. She will be responsible for all ethics and compliance functions at Bioventus, joins the company’s executive leadership team and will report directly to its CEO Ken Reali.
“I am very pleased to welcome Katrina as our new Chief Compliance Officer,” said Reali. “High ethics and compliance standards are paramount to our success and also important to our culture at Bioventus. I expect Katrina to build on the great foundation we have at this company as we continue to expand and grow to meet the needs of patients, physicians and payers.”
Church joins Bioventus after nearly 11 years with the Merz Group of companies where she served in several corporate counsel and compliance roles, most recently as Global Compliance Officer for Merz Pharma GmbH & Co KGaA. In 2020, Church was nominated for several industry awards for compliance training, and won the 2020 Women in Compliance Award for “Most Impactful Compliance Training Programme of the Year.”
Prior to Merz, Church served as a legal consultant to Stiefel Laboratories and in general counsel and corporate counsel roles with Connetics Corporation and VISX, Inc. She began her career as an attorney at Hopkins & Carley, a San Jose-based law firm. Church received her Juris Doctor from New York University School of Law and an AB magna cum laude from Duke University.
About Bioventus
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the company on LinkedIn and Twitter.
Media Contact: Thomas Hill, , [email protected]
Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Hyaluronic Acid Provides Knee OA Pain Relief with Lower Costs, Fewer Adverse Outcomes vs. Corticosteroids or Knee Arthroplasty
DURHAM, NC – August 13, 2020– Intra-articular hyaluronic acid (IHA) knee osteoarthritis (OA) pain relief treatments had lower total medical care costs vs. patients treated with intra-articular corticosteroids (ICS) or total knee arthroplasty (TKA). This according to a retrospective study, published in Seminars in Arthritis and Rheumatism.
The study involved an analysis of an insurance claims database whose eligible members were diagnosed with knee OA, followed for a four-year observation period and allocated to three cohorts: patients who received IHA only, those who received ICS only, and those who received TKA only. The analysis also found that patients in the IHA cohort had fewer adverse outcomes vs. patients in the ICS and TKA cohorts and had lower use/costs of opioids and prescription analgesics vs. patients in the ICS and TKA cohorts.
“Knee osteoarthritis is a lead cause of chronic pain and disability that affects more than 14 million Americans1. The treatment options available to these patients are limited and many are associated with complications. We have long known that introducing HA treatments earlier in the continuum of care of knee OA patients provides pain relief and safely allows them to enjoy a more active lifestyle,” said Alessandra Pavesio, Senior Vice President and Chief Science Officer, Bioventus.
“Now we know that with the efficacy and safety of HA treatments also come reduced total medical costs, fewer adverse events and a minimization of opioids and analgesics use. These findings should be very relevant to clinicians and payers working with these patients to improve treatment algorithms and minimize healthcare costs,” she added.
The study was funded by Bioventus and its authors include John Mackowiak, Ph.D., Center for Surgical Quality and Outcomes Research; John Jones, M.A., M.S., Bioventus; and Vinod Dasa, M.D., Louisiana State University.
To learn more this study, visit OAKneePainRelief.com/Healthcare-Provider/Haste/
About Bioventus
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com and follow the company on LinkedIn and Twitter.
Media Contact: Thomas Hill, , [email protected]
Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
- Deshpande BR, et al. Number of persons with symptomatic knee osteoarthritis in the US: impact of race and ethnicity, age, sex, and obesity. Arthritis Care Res 2016;68:1743-50
